Amarin

Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

Retrieved on: 
Donnerstag, Juli 20, 2023
Employment, Calendar, Securities and Exchange Commission (Nigeria), Professional corporation, Patient, Security (finance), Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Today the Board of Directors of Amarin Corporation plc (NASDAQ: AMRN) announced details regarding the compensation program for the Company’s new President and Chief Executive Officer (CEO), Patrick Holt, who was appointed to the role on July 18, 2023.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Today the Board of Directors of Amarin Corporation plc (NASDAQ: AMRN) announced details regarding the compensation program for the Company’s new President and Chief Executive Officer (CEO), Patrick Holt, who was appointed to the role on July 18, 2023.
  • The realizable value is at-risk equity and directly dependent upon the sustained performance of the Company’s share price and, thus, aligned with the interest of shareholders.
  • Mr. Holt has also agreed to purchase $300,000 worth of Amarin shares in the open market using personal funds.
  • Holt’s compensation addresses the long-standing frustration of shareholders who want executive compensation directly tied to the creation of shareholder value,” said Odysseas Kostas, M.D., the Chairman of the Board.

Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally

Retrieved on: 
Dienstag, Juli 18, 2023
Pressure, Telephone, EDT, Science, Professional corporation, IPE, International Partnership on Avian and Pandemic Influenza, Patient, MENA, Conference, Pharmaceutical industry, Renewable energy, Amarin

-- Company to Host Conference Call Today at 5:00 p.m. EDT --

Key Points: 
  • Over the last several months, the new Amarin Board of Directors and senior management team have conducted a comprehensive review of the business.
  • Amarin continues to generate revenue in the U.S. and maintains a strong cash position.
  • However, the restructuring announced today reflects the need for a thoughtful and significant change in strategy given the Company’s size, resources and challenging operating environment.
  • The Company expects these actions will reduce operating costs by approximately $40 million annually.

Amarin Appoints Patrick Holt as President and Chief Executive Officer

Retrieved on: 
Dienstag, Juli 18, 2023
Vaccine, Interim, Allergan, Sale, Amarin, Professional corporation, Patient, Physician, Management, Cordis, Merck

DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.
  • Aaron Berg, who served as Interim President and CEO since April 2023, will remain with the Company in a senior leadership role.
  • Mr. Holt brings more than 25 years of leadership in the life sciences industry and significant international operating experience.
  • Mr. Holt previously held a variety of senior executive positions across biopharmaceuticals and vaccines at Allergan and Merck.

Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)

Retrieved on: 
Mittwoch, Juni 21, 2023
China Biologic Products, Intellectual property, Research and development, Diabetes, Dyslipidemia, CV, Marketing, Saudi Food and Drug Authority, Cardiovascular disease, SHC, KSA, SFDA, TG, Amarin, Professional corporation, IPE, Development, Capsule, Publication, Patient, Risk, NHC, Kingdom, United Arab Emirates, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and its commercialization partner Biologix FZco, a company based in the United Arab Emirates and a pioneer in the distribution of pharmaceutical and biological products in the Middle East and North Africa, today announced that the Kingdom of Saudi Arabia’s (KSA) Saudi Food and Drug Authority (SFDA) has approved a new indication and label expansion for VASCEPA® (icosapent ethyl) capsules. VASCEPA is now the first and only drug approved by SFDA as an adjunct to statin therapy in adult patients with elevated triglycerides (TG) levels (≥150 mg/dL) who are at high-risk of cardiovascular (CV) events due to established cardiovascular disease or diabetes mellitus and at least one other risk factor for cardiovascular disease.

Key Points: 
  • VASCEPA is now the first and only drug approved by SFDA as an adjunct to statin therapy in adult patients with elevated triglycerides (TG) levels (≥150 mg/dL) who are at high-risk of cardiovascular (CV) events due to established cardiovascular disease or diabetes mellitus and at least one other risk factor for cardiovascular disease.
  • “We are excited that patients in KSA will now have the opportunity to benefit from the proven cardiovascular risk reduction with VASCEPA following the approval by the SFDA,” said Steven Ketchum, PhD., President, Research & Development and Chief Scientific Officer, Amarin.
  • “Today’s approval also marks an important step in our strategy to expand the global footprint where VASCEPA/VAZKEPA is indicated for cardiovascular risk reduction, built from the results seen in the REDUCE-IT outcomes trial.
  • Amarin is responsible for providing regulatory assistance, supply and maintaining intellectual property in the region.

Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China

Retrieved on: 
Donnerstag, Juni 1, 2023
Moyamoya disease, Partnership, Research and development, Diet, Hypertriglyceridemia, CVRR, Stroke, Cardiovascular disease, Ageing, Drug, CVD, Amarin, Professional corporation, Development, Death, Patient, World Heart Federation, Growth, NRDL, NMPA, Disease, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its commercial partner in China, EddingPharm (EDDING), has received regulatory approval for VASCEPA® (icosapent ethyl) from China’s National Medical Products Administration (NMPA). NMPA granted approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL).

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its commercial partner in China, EddingPharm (EDDING), has received regulatory approval for VASCEPA® (icosapent ethyl) from China’s National Medical Products Administration (NMPA).
  • NMPA granted approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL).
  • Following regulatory approval, EDDING is now focusing on National Reimbursement Drug Listing (NRDL) and preparing for commercial launch in China, expected by year-end, as well as on advancing regulatory submission and review for an additional indication in cardiovascular risk reduction (CVRR).
  • Following the NMPA approval for this indication, Amarin is now entitled to receive a regulatory milestone payment of $5 million.

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

Retrieved on: 
Freitag, Mai 12, 2023
CT, Plaque, Myocardial infarction, Diabetes, MB, Macrophage, NIRF, Triglyceride, Cardiovascular disease, Radiology, CAD, CTA, Research, Loyola University, IVUS, CH.B, Atherosclerosis, Amarin, Professional corporation, European Heart Journal: Cardiovascular Imaging, Ethyl eicosapentaenoic acid, Animal, Computed tomography angiography, Patient, European Heart Journal, Molecular imaging, American Heart, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

Key Points: 
  • EVAPORATE demonstrated that in statin-treated patients, VASCEPA/VAZKEPA significantly reduced plaque burden measured by serial coronary computed tomography angiography (CTA) compared with placebo.
  • VASCEPA/VAZKEPA improved mean distal segment FFRCT at 9- and 18-months follow-up compared with placebo (P = 0.02, P = 0.03 respectively).
  • “These new findings from two different studies provide important mechanistic information about VASCEPA/VAZKEPA and further elucidate its value in reducing cardiovascular events in at-risk patients,” said Nabil Abadir, MB.
  • We are proud to add to the body of research that further demonstrates the benefit of VASCEPA/VAZKEPA."

BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors

Retrieved on: 
Freitag, Mai 12, 2023
Bausch Health, Treasury, Laboratory, George, University, CFA, Biogen, Senior advisor, Chartered, History, Boston University, Amarin, Certification, Professional corporation, FleetBoston Financial, Business administration, Alcon, Stryker Corporation, Thermo Fisher Scientific, NESS, Corporation, George Washington University Law School, Chief, Treasurer, SVP, NYSE, BankBoston, Corporate development, Management

and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors.

Key Points: 
  • and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors.
  • Mr. Marks was also Chief Legal Officer and Corporate Secretary for InflaRX, N.V.
  • Earlier in his career, Mr. Dambach held several senior executive level roles within the financial services sector, including FleetBoston Financial Corporation and BankBoston.
  • Mr. Dambach holds the Chartered Financial Analyst (CFA) certification.

Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, Mai 3, 2023
England and Wales, Partnership, Operational definition, Telephone, HTA, GAAP, EDT, Amarin, Forecasting, Professional corporation, IPE, Patient, Investment, Research, Conference, Health technology assessment, Bank, Pharmaceutical industry, Airline, Cryptocurrency

-- Company to Host Conference Call Today at 8:00 a.m. EDT --

Key Points: 
  • To date in the U.K., Amarin is working to secure VAZKEPA patient access through local formulary negotiations, and we expect those negotiations will continue to progress throughout 2023.
  • In the first quarter of 2023, Amarin secured regulatory approval for VAZKEPA in New Zealand and Israel.
  • During the three months ended March 31, 2023, Amarin amended a supplier agreement resulting in a charge of $12.3 million.
  • The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

Retrieved on: 
Montag, April 17, 2023
Interim, Enterprise, Laboratory, Senior, Abbott Laboratories, Policy, Health, Marketing, Government, Professional corporation, Employment, Patient, Knowledge, U.S. Business Hall of Fame, Management, Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer (CEO).

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer (CEO).
  • “Aaron brings immense experience in the cardiovascular space and a strong commitment to Amarin and the value of VASCEPA® for patients worldwide.
  • Before joining Amarin, Mr. Berg served as President and Chief Executive Officer for Essentialis, Inc., a development stage pharmaceutical company where he led the company's work on triglyceride management.
  • With the addition of Mr. O’Connor, the Amarin Board of Directors now comprises 8 directors, including an Irish-domiciled Board member and all of whom are independent.

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

Retrieved on: 
Dienstag, April 4, 2023
Male, Partnership, Research and development, Diabetes, MOH, Cardiovascular disease, Woman, Amarin, Professional corporation, Ministry, Development, Death, Patient, Risk, Ageing, Female, Pharmaceutical industry, Health

DUBLIN, Ireland and BRIDGEWATER, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel’s Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to VAZKEPA (icosapent ethyl). The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]) and either established cardiovascular disease or diabetes and at least one other cardiovascular risk factor.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel’s Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to VAZKEPA (icosapent ethyl).
  • The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]) and either established cardiovascular disease or diabetes and at least one other cardiovascular risk factor.
  • “According to data from the Israeli Ministry of Health, heart diseases are the second leading cause of death in Israel, in both men and women, aged 45 and older.i Heart disease accounted for about one-sixth of all male and female deaths in recent years in Israel.i
    “The regulatory approval of VAZKEPA in Israel marks continued progress in our effort to bring this product to patients with residual cardiovascular risk around the world,” said Steven Ketchum, PhD., President, Research & Development and Chief Scientific Officer, Amarin.
  • “We are proud of this important milestone in that effort, and that patients in Israel may soon be able to access this important therapeutic option to address their residual cardiovascular risk.”
    Amarin has partnership discussions underway in this territory and will be preparing for potential pricing and reimbursement in Israel beginning in 2024.